デジタル治療薬の世界市場-2024～2031年

概要

デジタル治療薬の世界市場は、2023年に57億米ドルに達し、2031年には273億米ドルに達すると予測され、予測期間2024年～2031年のCAGRは21.6%で成長する見込みです。

デジタル治療薬（DTx）は、疾患の治療、予防、管理を支援する患者向けソフトウェアアプリケーションです。エビデンスに基づき、治療介入にソフトウェアを使用します。デジタル治療薬は、遠隔医療ライブセッションによる患者支援とモニタリングを同時に行うことができます。多くの慢性疾患患者は、モバイルアプリやウェブプラットフォームを通じて、自宅にいながら介入にアクセスすることができます。

市場力学：

促進要因と阻害要因

慢性疾患の有病率の上昇

世界のデジタル治療薬市場は、慢性疾患の有病率の上昇、行動変容の誘発、使いやすさ、患者の利便性、服薬コンプライアンスの改善などの利点によるデジタル治療薬への需要の高まり、新しいデジタル治療薬技術の進歩など、いくつかの要因によって成長しています。

糖尿病、高血圧、肥満などの慢性疾患が一般的になるにつれ、従来の医薬品を超えた効果的で長期的な解決策への需要が高まっています。例えば、メイヨークリニック2023によると、感染症と非感染症の間の移行は、公衆衛生の改善により1900年代初頭に始まった。個人の寿命が延びるにつれ、慢性疾患の罹患率とコストは増加の一途をたどり、2030年までにそのコストは47兆ドルに達すると推定されています。個人のライフスタイル、行動、地域社会の要因は、慢性疾患の発症と管理に大きく影響します。

したがって、人口の高齢化とライフスタイル要因による慢性疾患の有病率の上昇には、効果的な管理ソリューションが必要です。デジタル治療薬は、疾病予防と管理、拡張性、個別化のための革新的でコスト効率の高いツールを提供し、世界のヘルスケアの課題に取り組む上で極めて重要です。

治療薬採用の制限

市場開発の初期段階では、いくつかの要因によって市場が阻害されています。例えば、採用の制限、デジタル治療薬の高コスト、患者データのプライバシーに関する懸念、不安定な支払いモデルなどが挙げられます。

この市場は、病状を予防、管理、治療することを目的としたソフトウェアやデバイスをベースとした製品の新興分野です。しかし、サイバーセキュリティに関する問題が増加していることが、治療薬の採用を制限する大きな懸念となっています。患者は、医療データを保護する上でのリスクや脆弱性を懸念しています。特定のリスクやサイバー攻撃は、予測期間におけるこれらの製品の採用を抑制する原因となっています。

例えば、2022年9月、デジタル治療薬アプリに対するサイバー攻撃のリスクは以前と比較して増加しました。サイバー攻撃は、より多くのユーザーが利用できるようになり、患者の健康情報が増加したことが原因です。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 慢性疾患の罹患率の上昇
• 抑制要因
  • 治療法の採用を制限する
• 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 製品タイプ別

• ソフトウェア
• デバイス
• その他

第7章 用途別

• 糖尿病
• 肥満
• 心血管疾患（CVD）
• 中枢神経系（CNS）疾患
• 呼吸器疾患
• 禁煙
• 胃腸障害（GID）
• その他

第8章 販売チャネル別

• 企業間取引（B2B）
• 企業から消費者（B2C）

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Teladoc Health
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• 2Morrow Inc
• Omada Health, Inc.
• Resmed Inc
• Voluntis, Inc
• Kaia Health
• Biofourmis
• Click Therapeutics, Inc
• Welldoc's BlueStar
• Lark Technologies, Inc

第13章 付録

Overview

The global digital therapeutics market reached US$ 5.7 billion in 2023 and is expected to reach US$ 27.3 billion by 2031, growing at a CAGR of 21.6% during the forecast period 2024-2031.

Digital Therapeutics (DTx) is a patient-facing software application that aids in treating, preventing, or managing diseases. It is evidence-based and uses software for therapeutic intervention. Digital therapeutics allows simultaneous patient assistance and monitoring with live telemedicine sessions. Many chronic illness patients can access interventions from the comfort of their homes through mobile apps or web platforms.

Market Dynamics: Drivers & Restraints

Rise in the Prevalence of Chronic Diseases

The global digital therapeutics market is growing due to several factors such as the rise in the prevalence of chronic diseases, rising demands for digital therapeutics due to their advantages, such as induce behavioral change, user-friendliness, patient convenience, and improved drug compliance and novel digital therapeutics technological advances.

As chronic conditions like diabetes, hypertension, and obesity become more common, there is a growing demand for effective, long-term solutions beyond traditional pharmaceuticals. For instance, according to Mayo Clinic 2023, the transition between infectious and noncommunicable diseases began in the early 1900s due to improved public health. As individuals live longer, chronic disease prevalence and cost continue to rise, with the estimated cost reaching $47 trillion by 2030. Individual lifestyle, behaviors, and community factors significantly influence the development and management of chronic diseases.

Hence, the rising prevalence of chronic diseases due to aging populations and lifestyle factors necessitate effective management solutions digital therapeutics offers innovative, cost-efficient tools for disease prevention and management, scalability, and personalization, crucial in tackling global healthcare challenges.

Limiting the Adoption of Therapeutics

The market is hindered by several factors in the early phase stage of development some of them are like, limiting the adoption, high cost of digital therapeutics, the patient data privacy concerns and unstable payment models could hurt the market.

This market represents an emerging field of software and device-driven based products intended to prevent, manage or treat medical conditions. However, increasing issues related to cybersecurity are a major concern limiting the adoption of therapeutics. Patients are concerned about the risks and vulnerabilities in protecting their medical data. Certain risks and cyberattacks are responsible for the restrained adoption of these products in the forecast period.

For instance, in September 2022, the risk of cyberattacks on digital therapeutics apps increased as compared to previous years. The cyberattacks are due to the increased availability of more users and the rise in patient health information.

Segment Analysis

The global digital therapeutics market is segmented based on product type, application, sales channel, and region.

Product Type:

Softwares segment is expected to dominate the digital therapeutics market share

The softwares segment holds a major portion of the digital therapeutics market share and is expected to continue to hold a significant portion of the digital therapeutics market share during the forecast period.

The digital therapeutics market is segmented based on the product type as software, devices, and others. The software segment accounts for the highest market share due to the increasing demand for software to reduce healthcare costs worldwide. The software also provides regular online assistance from certified doctors. The market is dominated by several digital therapeutics software that helps the patients maintain their proper diet, track health data, and daily physical activities.

For instance, in June 2023 Digital Therapeutics Alliance (DTA) is announcing the launch of the Policymaker & Payor DTx Evaluation Toolkit, a comprehensive set of resources to enable global healthcare and digital technology leaders to broaden the understanding, adoption, and integration of clinically evaluated digital therapeutics (DTx) into healthcare.

Moreover, in January 2023 Curebase, a company committed to democratizing access to clinical trials, announced the release of its integrated software and services package for digital therapeutics (DTx) trials that accelerates enrollment and allows sponsors to launch their studies faster.

Diabetes segment is the fastest-growing segment in the digital therapeutics market share

The diabetes segment is the fastest-growing segment in the digital therapeutics market share and is expected to hold the market share over the forecast period.

Diabetes is a key chronic illness within the global digital therapeutics market, as many digital health solutions are aimed at addressing the problem of chronic diseases. Digital therapeutics such as mobile applications, wearable technology, and web-based systems are used to monitor blood glucose levels, compliance with medication, and lifestyle changes - diet and physical activity - thereby facilitating personalised interventions for diabetes management.

The segment is about to grow during the forecast period owing to the factors like, advancements in artificial intelligence, machine learning, and data analytics to provide real-time insights, personalized feedback, and predictive health management. Regulatory approvals for digital therapeutics targeting diabetes and increasing payer coverage further strengthen the segment's growth.

For instance, in January 2024, Eli Lilly has launched LillyDirect, a digital healthcare platform for US patients with obesity, migraine, and diabetes. The platform provides disease management resources, tailored support, and direct home delivery of select Lilly medicines through third-party pharmacy dispensing services. The aim is to simplify the patient experience and improve outcomes by offering more choices in healthcare access, including a convenient home delivery option for prescribed Lilly medicines. The company's chair and CEO, David A. Ricks, praised Lilly's approach.

Moreover, in October 2023, Better Therapeutics has launched its AspyreRx digital diabetes therapeutic app, becoming the first cognitive behavioral therapy (CBT) to receive FDA authorization for treating type 2 diabetes. The prescription digital therapeutic, formerly BT-001, provides CBT to patients aged 18 and older with type 2 diabetes.

Geographical Analysis

North America is expected to hold a significant position in the digital therapeutics market share

North America holds a substantial position in the digital therapeutics market and is expected to hold most of the market share due to the patient-centric healthcare approach for patient wellness, growing improvement in the reimbursement structure for digital therapeutics and others.

Moreover, an increasing number of collaborations and agreements amongst the key players to focus on the research and development of these products is expected to increase the introduction of these devices in the region.

For instance, in October 2024, The Center for Technology and Behavioral Health (CTBH) at the Geisel School of Medicine at Dartmouth is partnering with Boehringer Ingelheim to develop digital therapeutics for serious mental illness. The collaboration will use academic research and healthcare industry strengths to create tools to tackle the global mental health crisis. CTBH's founding director, Lisa Marsch, emphasizes the importance of bringing the best science to create effective tools and ensuring they have a real impact on people's lives globally.

Moreover, in October 2024, Click Therapeutics, Inc a leader in digital therapeutics as prescription medical treatments, announced the launch of Software-Enhanced Drug therapies, part of a new product offering called Click SE. With this launch, Click Therapeutics is creating a novel category of prescription digital therapeutic products in view of the increasing engagement in the U.S. Food and Drug Administration (FDA) draft guidance on the Prescription Drug-Use Related Software (PDURS). Hence, the above-mentioned factors help the North America region to grow during the forecast period.

Europe is growing at the fastest pace in the digital therapeutics market

Europe holds the fastest pace in the digital therapeutics market and is expected to hold most of the market share due to the driving forces for the Europe region, which poses a great potential for the global digital therapeutics market. The developed healthcare system and high level of integration of digital health in this region has made it possible to employ digital therapeutics in the treatment of many diseases such as diabetes, cardiovascular and mental disorders.

Moreover, funding from companies, supportive policies adopted by the governments, such as reimbursement of costs associated with the use of digital health solutions, as well as spending on healthcare digitization, have additional boosted the market. Besides, the combination of high incidence of chronic illnesses in Europe, which is accompanied by an older population, has created a possible use of remote patient monitoring systems and targeted health care services, which has contributed further to the market.

For instance, in August 2024, the Innovate UK recently declared the funding of 24 projects focused on the development of immersive digital mental health therapeutics. This award is part of Innovate UK's £20 Billion Mindset initiative that is aiding the expansion of immersive digital mental illness solutions within the UK. In addition to their support towards marketplaces, which focus on the rehabilitation of patients doling out therapeutic interventions, Mindset is establishing a strong ecosystem to help commercialize these innovations.

Competitive Landscape

The major global players in the digital therapeutics market include Teladoc Health, 2Morrow Inc, Omada Health, Inc, Resmed Inc , Voluntis, Inc, Kaia Health, Biofourmis, Click Therapeutics, Inc, Welldoc's BlueStar, Lark Technologies, Inc among others.

Emerging Players

The emerging players in the digital therapeutics market include Happify Health, Cognoa, Propeller Health, Akili Interactive Labs and among others.

Key Developments

• In August 2024, Otsuka Precision Health and Click Therapeutics have launched Rejoyn, a prescription digital therapeutic for treating major depressive disorder symptoms which is cleared by the FDA in March 2024, Rejoyn is used as an adjunct to clinician-managed outpatient care for adult patients aged 22 and older on antidepressant medication.
• In January 2023, Lupin Digital Health has launched its digital therapeutics solution, LYFE, which is an evidence-based heart care program designed by leading Indian cardiologists. LYFE helps patients improve their heart health through doctor-connected online and offline modules, FDA and CE-approved wearable devices that record vital parameters, notify caregivers and doctors about off-range vitals and emergencies, and offer medication reminders and 24x7 emergency and ambulance assistance.

Why Purchase the Report?

• To visualize the global digital therapeutics market segmentation based on product type, application, sales channel and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the digital therapeutics market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global digital therapeutics market report would provide approximately 70 tables, 65 figures, and 184 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Application
• 3.3. Snippet by Sales Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise in the Prevalence of Chronic Diseases
• 4.2. Restraints
  • 4.2.1. Limiting The Adoption of Therapeutics
• 4.3. Opportunity
  • 4.3.1. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Software*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Devices
• 6.4. Others

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.1.2. Market Attractiveness Index, By Application
• 7.2. Diabetes*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Obesity
• 7.4. Cardiovascular Diseases (CVD)
• 7.5. Central Nervous System (CNS) Diseases
• 7.6. Respiratory Diseases
• 7.7. Smoking Cessation
• 7.8. Gastrointestinal Disorders (GID)
• 7.9. Others

8. By Sales Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 8.1.2. Market Attractiveness Index, By Sales Channel
• 8.2. Business to Business (B2B) *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Business to Consumer (B2C)

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Teladoc Health*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. 2Morrow Inc
• 11.3. Omada Health, Inc.
• 11.4. Resmed Inc
• 11.5. Voluntis, Inc
• 11.6. Kaia Health
• 11.7. Biofourmis
• 11.8. Click Therapeutics, Inc
• 11.9. Welldoc's BlueStar
• 11.10. Lark Technologies, Inc

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1 About Us and Services
• 13.2 Contact Us